Uncommon Cures® was launched in 2023 with the mission to streamline orphan drug clinical development, which is unnecessarily slow, expensive, and likely to fail due to non-drug factors. Led by an expert team of physicians, nurses, and pharmacists with over 150 years of combined experience, Uncommon Cures collaborates with pharmaceutical and biotechnology sponsors to design and conduct highly efficient clinical trials for FDA and other regulatory agency approval. Some have called Uncommon Cures® a Clinical Research Organization (CRO) - it is not. Rather, it is a Clinical Research Program providing thought partnership and an efficient end-to-end solution called Uncommon Sense™ covering activities throughout orphan drug clinical development, including all legacy CRO and study site functions. By optimizing the clinical development process and prioritizing patient well-being, Uncommon Cures® aims to bring life-changing therapies to patients faster and more efficiently.
Company Details
- Employees
- 19
- Founded
- -
- Address
- 2 Wisconsin Circle,
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- http://www.UncommonCures.com
- HQ
- Chevy Chase, Maryland
Uncommon Cures® Questions
Uncommon Cures®'s website is http://www.UncommonCures.com
Uncommon Cures®'s LinkedIn profile is https://www.linkedin.com/company/uncommon-cures-inc
Uncommon Cures® has
19 employees.
View email and phone details for 19
employees at Uncommon Cures®.
Uncommon Cures®'s industry is
Research Services
Uncommon Cures®'s top competitors are
Orphan Therapeutics Accelerator,
Vibe Bio,
Acadia Pharmaceuticals Inc.,
National Organization For Rare Disorders,
Carna Health,
Bridgebio,
Ultragenyx,
Landmark Bio,
Dvlp Medicines,
Carexso.
Uncommon Cures®'s categories are Research Services
Uncommon Cures®'s founding year is 2023
